Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.
A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida ...
Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration.
Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback